文献速递肿瘤 PET/CT放射性药物与辐射防护

直接与间接89Zr PET成像追踪巨噬细胞

Tracking macrophages by direct and indirect 89Zr PET imaging.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-02-13

该研究在4T1乳腺癌小鼠模型中比较两种互补的PET/CT巨噬细胞追踪方法:新型[89Zr]Zr-DFO-抗F4/80抗体间接靶向原位巨噬细胞,以及[89Zr]Zr-oxine直接标记M0巨噬细胞。结果显示两种方法均可定量巨噬细胞分布与迁移,且直接标记在3.31 Gy吸收剂量下不影响巨噬细胞活力与表型。

要点

  • 100 μg/鼠[89Zr]Zr-DFO-抗F4/80可高对比度显示肿瘤内巨噬细胞
  • 静脉注射[89Zr]Zr标记M0巨噬细胞后24小时内迁移至肝脾和肿瘤
  • [89Zr]Zr-oxine标记在3.31 Gy吸收剂量下不影响巨噬细胞活力与表型

核心结论

  • 首次在乳腺癌原位同系小鼠模型中应用并比较两种互补PET/CT策略定量巨噬细胞浸润。
  • 间接法显示肿瘤相关巨噬细胞丰富,直接法显示血液巨噬细胞24小时内迁移至肿瘤。

研究设计与样本

  • 研究在雌性BALB/c小鼠的原位同系4T1乳腺癌模型中开展。
  • 开发[89Zr]Zr-DFO-抗F4/80抗体及非特异性对照抗体,并表征其特异性。
  • 用[89Zr]Zr-oxine直接标记小鼠来源巨噬细胞,评估放射标记对活力和表型的影响。
  • 采用PET成像和离体组织计数定量两种示踪剂的体内生物分布。

主要发现

  • [89Zr]Zr-DFO-抗F4/80在体外显示靶向特异性摄取。
  • 100 μg/鼠剂量下[89Zr]Zr-DFO-抗F4/80实现肿瘤驻留巨噬细胞的高对比度PET/CT显像,非特异性[89Zr]Zr-DFO-IgG2b未观察到该现象。
  • 静脉注射[89Zr]Zr标记M0巨噬细胞后迁移至肝脾,部分迁移至肿瘤。
  • [89Zr]Zr-oxine标记在3.31 Gy吸收剂量下不影响巨噬细胞活力与表型。

关键数值与推荐

  • [89Zr]Zr-DFO-抗F4/80剂量为每鼠100 μg时实现高对比度肿瘤巨噬细胞PET/CT显像。
  • [89Zr]Zr-oxine标记的巨噬细胞在3.31 Gy吸收剂量下活力和表型不受影响。

临床怎么用

  • 两种PET/CT策略可用于量化癌症中巨噬细胞分布与迁移,尤其适用于巨噬细胞群体受干预的治疗情境。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Tumour-associated macrophages are highly abundant in the tumour microenvironment, and their levels influence tumour progression and therapy response. Tracking macrophages by positron-emission tomography (PET) can yield critical information on the dynamics of macrophage infiltration, particularly in diseases such as breast cancer, in which tumour-associated macrophages are significant in the evolution of the tumour microenvironment. METHODS: Two complementary PET imaging methods were used to track macrophages. The first method used a novel [89Zr]Zr-labelled antibody that targets the murine F4/80 receptor, which is located on the cell surface of in situ macrophages. [89Zr]Zr-DFO-anti-F4/80 and a non-specific [89Zr]Zr-labelled control antibody were developed and characterised for their specificity. The second method involved directly labelling mouse-derived macrophages with [89Zr]Zr-oxine, and the effect of [89Zr]Zr-radiolabelling on macrophage viability and phenotype was evaluated. Using PET imaging and ex vivo tissue counting, the in vivo biodistribution of [89Zr]Zr-DFO-anti-F4/80 and [89Zr]Zr-labelled murine macrophages was quantified in female BALB/c mice bearing syngeneic, orthotopic 4T1 breast cancer tumours. RESULTS: [89Zr]Zr-DFO-anti-F4/80 showed target-specific uptake in vitro. At a dose of 100 μg DFO-anti-F4/80 per mouse, [89Zr]Zr-DFO-anti-F4/80 enabled visualization of tumour-resident macrophages by PET/CT with high contrast. This was not observed for non-specific [89Zr]Zr-DFO-IgG2b. PET/CT imaging showed that intravenously administered [89Zr]Zr-labelled M0 macrophages migrated to the liver and spleen, with a proportion of macrophages trafficking to the tumour. [89Zr]Zr-oxine labelling did not affect macrophage viability nor phenotype, even at an absorbed radiation dose of 3.31 Gy. CONCLUSION: For the first time, we have applied and compared two complementary PET/CT imaging strategies to quantify the infiltration of macrophages in an orthotopic, syngeneic murine model of breast cancer. First, PET/CT imaging using an “indirect” cell tracking approach with a new [89Zr]Zr-DFO-anti-F4/80 antibody radiotracer showed that resident tumour-associated macrophages are abundant in this syngeneic breast cancer model. Second, PET/CT imaging using [89Zr]Zr-labelled M0 macrophages showed that macrophages in the blood pool migrate to the tumour, within 24 h. These tools have utility in quantifying macrophage distribution and migration in cancer, particularly in the context of new and existing therapies in which macrophage populations are perturbed.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. De Santis V, Flaherty R, Banu A, et al. Tracking macrophages by direct and indirect 89Zr PET imaging. Eur J Nucl Med Mol Imaging. 2026. PMID: 41686219. doi:10.1007/s00259-025-07752-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。